Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Talmapimod

Next Previous
Drug Profile

Talmapimod

Alternative Names: SCIO-469

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Scios
  • Class Analgesics; Anti-inflammatories; Antirheumatics; Indoles; Skin disorder therapies
  • Mechanism of Action P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Skin disorders
  • Discontinued Dental pain; Multiple myeloma; Myelodysplastic syndromes; Rheumatoid arthritis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Skin-disorders in USA (Topical)
  • 29 Oct 2008 Final efficacy, adverse events & pharmacokinetics data from the phase II SPRiNG trial in Rheumatoid arthritis presented at the 72nd Annual Scientific Meeting of the American College of Rheumatology and the 43rd Annual Meeting of the Association of Rheumatology Health Professionals (ACR/ARHP-2008)
  • 29 Apr 2005 Phase-I/II clinical trials in Myelodysplastic syndromes in USA (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top